Additionally, the combination of anlotinib and gemcitabine has proven effective in suppressing the growth of cholangiocarcinoma cell lines while concurrently increasing the expression of cleaved PARP/PARP and cleaved caspase-3/caspase-3 proteins [29]. The gene discussed is CASP3; the disease is cholangiocarcinoma.